PESG Report: Inspira Technologies Breaks new Ground with Positive Clinical Data for AI-Powered Blood Sensor Exceeding Expectations
Inspira Technologies (NASDAQ: IINN) has achieved breakthrough clinical results for its AI-powered HYLA blood sensor, demonstrating 96% accuracy in key parameters compared to traditional blood analyzers and 92.3% accuracy in detecting oxygen deficiencies.
The clinical study, conducted at Sheba Hospital, validated the sensor's capabilities across 6 patients undergoing open-heart surgery. The HYLA sensor operates as a clip-on device that monitors blood parameters in real-time during cardiopulmonary bypass procedures.
This development strengthens Inspira's position in both the $5.7 billion blood gas analyzer market and the $19 billion mechanical ventilation market. The company's INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024, is being deployed in U.S. hospitals through Glo-Med Networks.
Additionally, Inspira reported positive results from its collaboration with Ennocure MedTech , showing a 95% reduction in bacterial presence within 4 hours in preventing bloodstream infections.
Inspira Technologies (NASDAQ: IINN) ha raggiunto risultati clinici straordinari per il suo sensore ematico HYLA alimentato da intelligenza artificiale, dimostrando un 96% di accuratezza nei parametri chiave rispetto agli analizzatori di sangue tradizionali e un 92,3% di accuratezza nel rilevamento delle carenze di ossigeno.
Lo studio clinico, condotto presso il Sheba Hospital, ha convalidato le capacità del sensore su 6 pazienti sottoposti a intervento di cardiochirurgia. Il sensore HYLA funziona come un dispositivo clip-on che monitora i parametri ematici in tempo reale durante le procedure di bypass cardiopolmonare.
Questo sviluppo rafforza la posizione di Inspira sia nel mercato degli analizzatori di gas ematici da 5,7 miliardi di dollari sia nel mercato della ventilazione meccanica da 19 miliardi di dollari. Il sistema INSPIRA ART100 dell'azienda, che ha ricevuto l'approvazione FDA 510(k) a maggio 2024, è in fase di distribuzione negli ospedali statunitensi attraverso Glo-Med Networks.
Inoltre, Inspira ha riportato risultati positivi dalla sua collaborazione con Ennocure MedTech, mostrando una riduzione del 95% della presenza batterica entro 4 ore nella prevenzione delle infezioni del flusso sanguigno.
Inspira Technologies (NASDAQ: IINN) ha logrado resultados clínicos innovadores para su sensor de sangre HYLA impulsado por inteligencia artificial, demostrando una exactitud del 96% en parámetros clave en comparación con los analizadores de sangre tradicionales y una exactitud del 92,3% en la detección de deficiencias de oxígeno.
El estudio clínico, realizado en el Sheba Hospital, validó las capacidades del sensor en 6 pacientes que se sometieron a cirugía cardiaca. El sensor HYLA funciona como un dispositivo de clip que monitorea los parámetros sanguíneos en tiempo real durante los procedimientos de bypass cardiopulmonar.
Este desarrollo refuerza la posición de Inspira tanto en el mercado de analizadores de gases en sangre de 5.7 mil millones de dólares como en el mercado de ventilación mecánica de 19 mil millones de dólares. El sistema INSPIRA ART100 de la compañía, que recibió la aprobación de la FDA 510(k) en mayo de 2024, se está implementando en hospitales de EE. UU. a través de Glo-Med Networks.
Además, Inspira informó resultados positivos de su colaboración con Ennocure MedTech, mostrando una reducción del 95% en la presencia bacteriana en 4 horas para prevenir infecciones en el torrente sanguíneo.
Inspira Technologies (NASDAQ: IINN)는 인공지능 기반의 HYLA 혈액 센서에 대한 획기적인 임상 결과를 달성하였으며, 전통적인 혈액 분석기와 비교하여 주요 매개변수에서 96%의 정확도를, 산소 결핍을 감지하는 데 있어 92.3%의 정확도를 보여주었습니다.
이 임상 연구는 셰바 병원에서 진행되었으며, 심장 수술을 받는 6명의 환자를 대상으로 센서의 능력을 검증했습니다. HYLA 센서는 심폐 우회 수술 중 혈액 매개변수를 실시간으로 모니터링하는 클립형 장치로 작동합니다.
이 발전은 Inspira가 57억 달러 규모의 혈액 가스 분석기 시장과 190억 달러 규모의 기계 환기 시장에서의 위치를 강화합니다. 이 회사의 INSPIRA ART100 시스템은 2024년 5월에 FDA 510(k) 승인을 받았으며, Glo-Med Networks를 통해 미국 병원에 배포되고 있습니다.
또한 Inspira는 Ennocure MedTech와의 협력에서 긍정적인 결과를 보고하였으며, 혈류 감염 예방을 위해 4시간 이내에 박테리아 존재를 95% 감소시키는 효과를 보였습니다.
Inspira Technologies (NASDAQ: IINN) a obtenu des résultats cliniques révolutionnaires pour son capteur sanguin HYLA alimenté par l'IA, démontrant une précision de 96% sur des paramètres clés par rapport aux analyseurs de sang traditionnels et une précision de 92,3% dans la détection des carences en oxygène.
L'étude clinique, réalisée à l'hôpital Sheba, a validé les capacités du capteur sur 6 patients subissant une chirurgie cardiaque. Le capteur HYLA fonctionne comme un dispositif clip-on qui surveille en temps réel les paramètres sanguins lors des procédures de circulation extracorporelle.
Ce développement renforce la position d'Inspira tant sur le marché des analyseurs de gaz sanguins de 5,7 milliards de dollars que sur le marché de la ventilation mécanique de 19 milliards de dollars. Le système INSPIRA ART100 de l'entreprise, qui a reçu l'autorisation FDA 510(k) en mai 2024, est déployé dans les hôpitaux américains via Glo-Med Networks.
De plus, Inspira a rapporté des résultats positifs de sa collaboration avec Ennocure MedTech, montrant une réduction de 95% de la présence bactérienne en 4 heures pour prévenir les infections du sang.
Inspira Technologies (NASDAQ: IINN) hat bahnbrechende klinische Ergebnisse für seinen KI-gestützten HYLA-Blutsensor erzielt, der eine 96%ige Genauigkeit bei wichtigen Parametern im Vergleich zu traditionellen Blutanalysatoren und eine 92,3%ige Genauigkeit bei der Erkennung von Sauerstoffmangel zeigt.
Die klinische Studie, die im Sheba Hospital durchgeführt wurde, validierte die Fähigkeiten des Sensors bei 6 Patienten, die sich einer Herzoperation unterzogen. Der HYLA-Sensor funktioniert als Clip-on-Gerät, das während der kardiopulmonalen Bypassverfahren die Blutparameter in Echtzeit überwacht.
Diese Entwicklung stärkt die Position von Inspira sowohl im 5,7 Milliarden Dollar schweren Markt für Blutgasanalysegeräte als auch im 19 Milliarden Dollar schweren Markt für mechanische Beatmung. Das INSPIRA ART100-System des Unternehmens, das im Mai 2024 die FDA 510(k)-Zulassung erhielt, wird über Glo-Med Networks in US-Krankenhäusern eingesetzt.
Darüber hinaus berichtete Inspira von positiven Ergebnissen aus der Zusammenarbeit mit Ennocure MedTech, die eine 95%ige Reduktion der bakteriellen Präsenz innerhalb von 4 Stunden zur Verhinderung von Blutstrominfektionen zeigt.
- Exceptional clinical trial results with 96% accuracy
- FDA 510(k) clearance received for INSPIRA ART100
- Strong market potential in both blood gas analyzer and mechanical ventilation sectors
- Successful validation at prestigious Sheba Hospital
- Promising bacterial reduction results from Ennocure collaboration
- FDA submission for HYLA not until H2 2025
- Technology still in early deployment phase
- Faces competition in established medical device markets
- Clinical trial conducted on relatively small patient group
Inspira Technologies* reports groundbreaking clinical results for its AI-powered HYLA blood sensor, achieving
Promising Clinical Validation at Premier Medical Institution
The clinical study, conducted at Sheba Hospital (ranked among the world's top 8 hospitals by Newsweek), successfully demonstrated the HYLA sensor's capabilities across 6 patients undergoing open-heart surgery. The clip-on device monitored blood parameters in real-time as blood circulated through the cardiopulmonary bypass system, achieving impressive concordance with conventional laboratory testing methods. Notably, the study also validated a new indicator for identifying oxygen deficiencies, showing
This clinical validation at one of the world's premier medical institutions represents a significant de-risking event for the company's core technology. As Dagi Ben-Noon, CEO of Inspira, noted, "Achieving
Expanding Technology Ecosystem Shows Commercial Progress
The successful HYLA clinical results come amid accelerating commercial momentum for Inspira's broader product ecosystem. The company's INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024 for cardiopulmonary bypass procedures, is now being deployed at leading
Additionally, in February 2025, Inspira reported positive initial results from its collaboration with Ennocure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream infections. Ex-vivo testing demonstrated a
Inspira’s Strategy Targets Multiple High-Value Markets
The successful clinical validation of the HYLA blood sensor represents a crucial step in Inspira's strategy to penetrate multiple high-value medical technology markets. As a standalone technology, HYLA targets the blood gas analyzer market, which the company projects will reach
Inspira's approach of combining AI-enhanced monitoring capabilities with innovative respiratory support solutions addresses a critical unmet need in healthcare. With approximately 20 million patients annually requiring mechanical ventilation globally and mortality rates exceeding
Click here to Subscribe for more updates like this
Latest News from Inspira:
-
Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving
96% Accuracy -
Inspira Achieves Positive Results of Above
95% For Preventing Bloodstream Infections - Inspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor
* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by PESG Research, a brand affiliated with the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305859034/en/
PESG Editorial Desk
ronald@futuremarketsresearch.com
Source: PESG Research
FAQ
What accuracy rate did Inspira's HYLA blood sensor achieve in clinical trials?
How many patients were involved in IINN's HYLA blood sensor clinical study?
When will Inspira Technologies (IINN) submit HYLA for FDA approval?
What market size is Inspira Technologies (IINN) targeting with its HYLA technology?
What were the results of IINN's collaboration with Ennocure MedTech?
